CSF2 and acute myeloid leukemia: Interestingly, we also provided evidence that administration of a supra-physiological dose of GM-CSF significantly blocked the efficacy of PyQ. In conclusion, we have shown that PyQ inactivates the CD45/GM-CSF pathway on human AML cells and could be used as a novel therapeutic agent for the treatment of AML.